The Cancer Molecular Imaging Program Area is composed of 18 members, spanning 7 Departments within UCLA. In the past competing cycle, investigators from this Program authored 265 publications, of which 232 (88%) were inter-programmatic and 89 (34%) intra-programmatic. 71 (27%) were placed in high-impact ournals. Nine members of this Program Area used 6 out of the 8 Shared Resources that are currently funded by the JCCC. During the current funding year, peer-reviewed funding totaled $4.4 million in total costs, including $3.8 million from the National Cancer Institute. As with other Program Areas, JCCC fosters a number of interactive activities and many of the Shared Resources that support investigators in the CMI Program Area. During the current grant cycle, funds from the JCCC in the form of CCSG Developmental Funds, institutional support and philanthropic gifts to the CMI Program Area total $317,584. These funds supported Seed Grants, recruitment/retention &Program Area Leadership support. Four of the Program Area Members were the recipients of JCCC support. Molecular imaging is a powerful set of approaches to reveal functional changes in living subjects that has enabled compelling insights into human health and disease. The newly proposed JCCC Cancer Molecular Imaging Program Area brings together investigators with a common focus on employing molecular imaging tools to investigate cancer in living individuals, from laboratory rodent models to patients. The efforts of CMI investigators are organized around four main themes. 1) Development of instrumentation and analytical tools. Moving molecular imaging forward requires constant development and improvement in instrumentation to provide higher resolution, sensitivity, and quantitative measurement of biological molecules and processes in vivo. 2) Development of novel molecular imaging approaches. CMI Program Area members have been leaders in the field of molecular imaging, with significant contributions in novel tracers, imaging gene expression using reporter genes, developing animal models to exploit the advantages of non-invasive, repeated and quantitative imaging, and in development of multimodality imaging instrumentation and analytic procedures. These tools are employed in the study of cancer initiation and progression, metastatic spread, and response to treatment, in preclinical models. 3) Imaging immune responses and response to immunotherapy. An important focus of the CMI Program Area is to develop the tools to monitor immune responses and follow the effects of cancer immunotherapy in living individuals. 4) Translation of imaging technologies to clinical contexts for cancer patients. Ultimately, the goal of the CMI Program Area is to improve the understanding, detection, and treatment of cancer. CMI Program Area members pursue translational goals that include both determining the best use of currently available molecular tracers in the clinic (e.g., FDG-PET, FLT-PET) as well as translating new molecular tracers through clinical evaluation.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California Los Angeles
Los Angeles
United States
Zip Code
Yang, Qing; Fung, Wing K; Li, Gang (2018) Sample size determination for jointly testing a cause-specific hazard and the all-cause hazard in the presence of competing risks. Stat Med 37:1389-1401
Seo, Jai Woong; Tavaré, Richard; Mahakian, Lisa M et al. (2018) CD8+ T-Cell Density Imaging with 64Cu-Labeled Cys-Diabody Informs Immunotherapy Protocols. Clin Cancer Res 24:4976-4987
Ribas, Antoni; Wolchok, Jedd D (2018) Cancer immunotherapy using checkpoint blockade. Science 359:1350-1355
Wang, Hong; Chen, Xiaolin; Li, Gang (2018) Survival Forests with R-Squared Splitting Rules. J Comput Biol 25:388-395
Yu, Jingyi; Seldin, Marcus M; Fu, Kai et al. (2018) Topological Arrangement of Cardiac Fibroblasts Regulates Cellular Plasticity. Circ Res 123:73-85
Hong, Aayoung; Moriceau, Gatien; Sun, Lu et al. (2018) Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma. Cancer Discov 8:74-93
Epeldegui, Marta; Magpantay, Larry; Guo, Yu et al. (2018) A prospective study of serum microbial translocation biomarkers and risk of AIDS-related non-Hodgkin lymphoma. AIDS 32:945-954
Hsu, Jeffrey J; Lu, Jinxiu; Umar, Soban et al. (2018) Effects of teriparatide on morphology of aortic calcification in aged hyperlipidemic mice. Am J Physiol Heart Circ Physiol 314:H1203-H1213
Woo, Jin Seok; Srikanth, Sonal; Kim, Kyun-Do et al. (2018) CRACR2A-Mediated TCR Signaling Promotes Local Effector Th1 and Th17 Responses. J Immunol 201:1174-1185
Patananan, Alexander N; Sercel, Alexander J; Teitell, Michael A (2018) More than a powerplant: the influence of mitochondrial transfer on the epigenome. Curr Opin Physiol 3:16-24

Showing the most recent 10 out of 767 publications